A new targeted treatment for anaplastic large cell lymphoma
Stopping protein activity to stop anaplastic large cell lymphomas from growing.
Using existing drugs in a new way to treat high-risk acute lymphoblastic leukaemia
Finding drugs which target genes that drive high-risk acute lymphoblastic leukaemia.
Using synthetic antibodies to treat diffuse midline gliomas
Creating antibodies in the lab to treat diffuse midline gliomas and testing their effectiveness.
Targeting proteins to fight acute myeloid leukaemia
Understanding how proteins act inside acute myeloid leukaemia cells, to find new drug targets.
Using genetics to understand why acute myeloid leukaemia cells don’t respond to treatment
Looking at the genetics of bone marrow samples to see which genes affect resistance to treatment.
A living review of new treatments for children and young people with relapsed and refractory rhabdomyosarcoma
Developing a living systematic review of studies into new treatments for relapsed and refractory rhabdomyosarcoma.
Can radiotherapy near the spleen lead to severe infections later in life?
Looking into whether survivors of childhood cancer are at risk of severe infections.
New treatments for relapsed rhabdomyosarcoma
Developing better models of rhabdomyosarcoma to test available treatments.
Paediatric Hepatic International Tumour Trial
Developing more effective treatments for patients who have a low chance of survival, while reducing treatment and side effects for other patients.